Headlines about ABIOMED (NASDAQ:ABMD) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ABIOMED earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.6270056756516 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Brokerages Expect ABIOMED, Inc. (NASDAQ:ABMD) to Announce $0.37 EPS (americanbankingnews.com)
- ABIOMED, Inc. (ABMD) Reached a New 52-Week High - First News 24 (firstnewspaper24.com)
- Pumped Up About Abiomed Collar Play - TheStreet.com (realmoneypro.thestreet.com)
- Abiomed Inc (ABMD) Relative Momentum Continuing to Trend Higher - Evergreen Caller (evergreencaller.com)
- PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance (finance.yahoo.com)
Shares of ABIOMED (NASDAQ:ABMD) opened at 151.01 on Friday. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of 88.31 and a beta of 0.20. ABIOMED has a one year low of $95.14 and a one year high of $151.22. The company has a 50 day moving average of $143.76 and a 200-day moving average of $128.87.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The firm had revenue of $132.47 million during the quarter, compared to analysts’ expectations of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The firm’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 EPS. On average, analysts anticipate that ABIOMED will post $2.24 earnings per share for the current year.
A number of equities research analysts have recently issued reports on ABMD shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $140.00 target price (up previously from $135.00) on shares of ABIOMED in a report on Monday, July 10th. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $165.00 target price on shares of ABIOMED in a report on Friday. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $160.00 price objective (up previously from $145.00) on shares of ABIOMED in a report on Thursday, July 27th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $156.86.
WARNING: This report was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://stocknewstimes.com/2017/08/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-abiomed-nasdaqabmd-stock-price.html.
In other ABIOMED news, COO David M. Weber sold 21,250 shares of ABIOMED stock in a transaction dated Monday, May 8th. The stock was sold at an average price of $130.89, for a total value of $2,781,412.50. Following the completion of the sale, the chief operating officer now owns 123,771 shares in the company, valued at approximately $16,200,386.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO David M. Weber sold 16,500 shares of ABIOMED stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $147.63, for a total value of $2,435,895.00. Following the completion of the sale, the chief operating officer now owns 125,122 shares of the company’s stock, valued at approximately $18,471,760.86. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,129 shares of company stock valued at $9,508,475. 7.00% of the stock is currently owned by company insiders.
About ABIOMED
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
